Organogenesis Holdings (ORGO) Depreciation and Depletion (2018 - 2025)
Organogenesis Holdings' (ORGO) quarterly Depreciation and Depletion came in at $4.1 million in Q4 2025, up 12.48% year-on-year from $3.6 million in Q4 2024, and up 0.92% quarter-over-quarter from $4.0 million in Q3 2025.
Organogenesis Holdings (ORGO) Depreciation and Depletion (2018 - 2025) Analysis & Trends
Organogenesis Holdings' Depreciation and Depletion history runs 8 years deep, the most recent figure standing at $4.1 million for Q4 2025.
- On a quarterly basis, Depreciation and Depletion rose 12.48% year-over-year to $4.1 million in Q4 2025; TTM through Dec 2025 was $15.3 million, a 12.11% increase from a year earlier, with the FY2025 full-year figure at $15.3 million, up 12.11% from the prior year.
- Depreciation and Depletion rose to $4.1 million in Q4 2025 per ORGO's latest filing, from $4.0 million in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $4.1 million in Q4 2025 and bottomed at $1.0 million in Q1 2021.
- The 5-year median for Depreciation and Depletion is $2.6 million (2023), against an average of $2.5 million.
- Across the five-year window, Depreciation and Depletion dropped 24.83% in 2022 and jumped 100.0% in 2023, its largest moves.
- Year by year, Depreciation and Depletion stood at $1.8 million in 2021, then decreased by 14.51% to $1.5 million in 2022, then jumped by 96.96% to $3.0 million in 2023, then rose by 21.23% to $3.6 million in 2024, then gained by 12.48% to $4.1 million in 2025.
- Per Business Quant, the three latest ORGO Depreciation and Depletion figures stand at $4.1 million (Q4 2025), $4.0 million (Q3 2025), and $3.7 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | 36.00 Mn |
| 3 | Zoetis | 32.70 Bn | 30.76 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.73 Bn | 23.67 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 21.60 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.18 Bn | 18.37 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 28.00 Mn |
| 10 | Organogenesis Holdings | 318.21 Mn | 226.12 Mn | 11.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.07 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | 3.62 Mn |
| Dec 31, 2024 | 3.62 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Sep 30, 2023 | 2.54 Mn |
| Sep 30, 2023 | 2.54 Mn |